Work

Formulation and Evaluation of Thymoquinone-Loaded Transferosome Gel For the Treatment of Arthritis

Year: 2026
Type: article
Abstract: Background: Arthritis is a debilitating chronic inflammatory condition with significant global burden. Thymoquinone (TQ), the principal bioactive constituent of Nigella sativa, possesses potent anti-inflammatory, antioxidant, and immunomodulatory properties. However, its BCS Class II classification, poor aqueous solubility (865.3 mg/L at 25°C) and log P of 2.20 restrict oral bioavailability. Transfersomes—ultra-deformable elastic phospholipid vesicles incorporating edge activators—offer a viable transdermal platform to overcome the stratum corneum barrier and achieve sustained local drug delivery at arthritic joints. Materials and Methods: TQ-loaded transfersomes were prepared by high-shear homogenisation (HSH) using soy lecithin, L-α-phosphatidylcholine (L-α-PC), and Tween 80. A three-factor, three-level Box–Behnken design (BBD; 15 runs; Design-Expert v12) was employed with soy lecithin concentration (A: 150–350 mg), L-α-PC (B: 100–300 mg), and RPM (C: 8000–10,000) as independent variables. Responses evaluated were zeta potential, particle size, encapsulation efficiency (EE%), and drug loading (DL%). FTIR compatibility studies and UV calibration (λmax 258 nm; R²=0.9987) were performed. Morphology was assessed by scanning electron microscopy (SEM; SRMIST Apreo S; 27 Feb 2024). In vitro drug release was conducted via Franz diffusion cells (cellophane membrane; pH 5.8; 37°C; 6 h). The optimised transferosome (F6) was incorporated into Carbopol 934 gel bases at three concentrations (TG1: 250 mg; TG2: 500 mg; TG3: 1000 mg) and evaluated for appearance, pH, spreadability, grittiness, and in vitro release. Results: FTIR spectra confirmed drug–excipient compatibility across all physical mixtures. SEM revealed spherical transfersomes with concentration-dependent clustering. Zeta potential ranged from −21.1 to −34.6 mV across 15 runs; optimal F6: −30.3 mV. Particle size ranged 316.6–715.6 nm; minimum achieved at soy lecithin 150–250 mg / L-α-PC 100–200 mg / 10,000 rpm. EE ranged from 54.53% (F5) to 77.1% (F1); DL ranged 16.97%–27.89% (maximum at soy lecithin 250 mg / L-α-PC 200 mg). Six-hour cumulative drug release (%CDR): F6=89.87%, F8=88.56%, F10=87.43%, F7=87.23%, F12=86.89%, F1=84.67%. Gel evaluation: TG2 exhibited optimal spreadability (1.99±0.08 g·cm/s), skincompatible pH (5.2), absence of grittiness, and highest CDR of 90.08% at 6 h. All gel formulations appeared clear and transparent. Conclusions: BBD-driven optimisation identified F6 as the optimal transferosome formulation. The F6-loaded TG2 gel demonstrated sustained transdermal drug release, ideal biopharmaceutical performance, and excellent topical applicability, establishing a promising platform for arthritis management. In vivo pharmacokinetic and antiinflammatory validation is warranted.
Language: English
Open Access status: bronze
OpenAlex ID: W7235558257
FWCI:
Cites: 18
Cited by:
Related to: 10